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The designations employed and the presentation of the 
material in the Global Synthetic Drugs Assessment 2020 do 
not imply the expression of any opinion whatsoever on 
the part of the Secretariat of the United Nations concern-
ing the legal status of any country, territory, city or area, 
or of its authorities, or concerning the delimitation of its 
frontiers or boundaries. 
Countries and areas are referred to by the names that were 
in official use at the time the relevant data were collected. 
Since there is some scientific and legal ambiguity about 
the distinctions between “drug use”, “drug misuse” and 
“drug abuse”, the neutral term “drug use” is used in this 
report. The term “misuse” is used only to denote the 
non-medical use of pharmaceutical drugs. 
All uses of the word “drug” and the term “drug use” in this 
report refer to substances controlled under the three 
International Drug Control Conventions, and their 
non-medical use. 
All analysis contained in this report is based on official 
data submitted by Member States to the UNODC 
through the annual report questionnaire unless indicated 
otherwise. 
References to dollars are to United States dollars, unless 
otherwise stated. 




 AOTP  Afghan Opiate Trade 
Project (UNODC)
 ATS  Amphetamine-type 
stimulants




 CARICC  Central Asian Regional 
Information and 
Coordination Centre For 
Combating The Illicit 
Trafficking Of Narcotic 
Drugs, Psychotropic 
Substances And Their 
Precursors
 CNS Central nervous system 
 COVID-19 Coronavirus disease 2019
 DEA  Drug Enforcement 
Administration (United 
States)
 DNC  Department of Narcotics 
Control (Bangladesh)
 ECOSOC  United Nations Economic 
and Social Council
 EMCDDA  European Monitoring 
Centre for Drugs and Drug 
Addiction
 Europol  European Union Agency 
for Law Enforcement 
Cooperation
 EWA  Early Warning Advisory  
on New Psychoactive 
Substances (UNODC)
 FSPP  Fentanyl Signature 
Profiling Program (United 
States)
 HIV  human immunodeficiency  
virus
 INCB  International Narcotics 
Control Board
 INR Indian Rupees
 ISIS/DAESH  Islamic State of Iraq and 
the Levant
 NCB  Narcotic Control Bureau 
(India)
 NDLEA  National Drug Law 
Enforcement Agency 
(Nigeria)
 NFLIS  National Forensic 
Laboratory Information 
System (United States)
 NPS  New psychoactive 
substance(s)
 PICTs  Pacific island countries 
and territories
 SMART  Global Synthetics 
Monitoring: Analyses, 
Reporting and Trends 
Programme
 STI  Sexually-transmitted 
infections





 2C-B  2,5-dimethoxy-4- 
bromophenethylamine
 2C-C  2,5-dimethoxy- 
4-chlorophenethylamine
 2C-E  2,5-dimethoxy- 
4-ethylphenethylamine
 2C-I  2,5-dimethoxy- 
4-iodophenethylamine
 3-MMC 3-methylmethcathinone








 5F-MMB-PICA  methyl (1-(5-fluoropentyl)- 
1H-indole-3-carbonyl)
valinate












 alpha-PVP  alpha-pyrrolidino - 
valerophenone
 ANPP  4-anilino-N- 
phenethylpiperidine
 APAA  alpha-phenylaceto- 
acetamide








 MAPA  methyl alpha- 
phenylacetoacetate
 MDMA  3,4-methylenedioxy- 
methamphetamine
 MDPV  3,4-methylenedioxy- 
pyrovalerone
















Early warning systems 
In recent years, over 1,000 new psychoactive substances 
(NPS) have emerged on illicit drug markets. The sheer 
number of substances and the dynamic nature of the NPS 
market pose serious challenges to the timely identifica-
tion and development of responses to the emerging public 
health threats associated with this trend. The availability 
of early warning systems at the national, regional and 
international level offer opportunities to avert potential 
crises through prompt information sharing among stake-
holders so that the risks posed by synthetic drugs can be 
identified and mitigated. Such systems can represent valu-
able additions to the traditional monitoring of drug 
supply and demand indicators and facilitate 
 awareness-raising and the communication of potential 
risks. At the global level, UNODC launched its Early 
Warning Advisory on NPS (EWA) in 2013 as an Internet-
based knowledge and monitoring platform containing 
information on over 1,000 substances reported by more 
than 125 countries and territories.1
International scheduling
Drug control systems at both the national and inter-
national level have been confronted by the rapid emer-
gence of an unprecedented number of different NPS. In 
response, many Member States have explored and suc-
cessfully used a wide range of legislative approaches 
including generic, analogue and specific NPS-related leg-
islation in addition to the individual listing of substances. 
Nevertheless, placing potentially harmful substances 
under legal control can be a lengthy process as it often 
requires evidence gathering and a scientific review of 
harms. Furthermore, differences in the control status of 
various substances between countries can create opportu-
nities for the illicit manufacture and trafficking of such 
substances by criminal organizations. Placing the most 
harmful, prevalent and persistent substances under inter-
national control therefore remains an important measure 
for protecting human health and welfare while ensuring 
access to drugs for medical and scientific purposes.  
1 The UNODC Early Warning Advisory on NPS may be accessed at 
www.unodc.org/nps
Enhanced precursor control
The numerous and widespread licit uses of precursor chem-
icals used in the illicit manufacture of synthetic drugs in a 
globalized economy render control and law enforcement 
efforts particularly difficult. This situation is exacerbated by 
two significant overlapping developments in illicit manu-
facture: the switching from controlled to non-controlled 
precursors and the use of “designer” precursors. A possible 
approach would be to proactively control known chemi-
cals, which have no known legitimate uses, but could 
potentially be used in the illicit manufacture of controlled 
precursors or drugs.2 With respect to the diversion of phar-
maceutical preparations used in illicit drug manufacture 
such as ephedrine and pseudoephedrine, the strengthening 
of medicine legislation, monitoring systems and rational 
prescribing could decrease rates of diversion.
Access to controlled substances  
for medical and scientific purposes
Over the past years the non-medical use of opioids includ-
ing fentanyl and tramadol has increased significantly. The 
ongoing opioid crisis, which has affected North America 
and parts of Africa and the Middle East, calls for a meas-
ured approach to stem the non-medical use of inter-
nationally controlled opioids and at the same time avoid a 
negative impact on the accessibility and availability of 
these opioids for pain management and palliative care. 
This could include estimating national requirements for 
controlled substances,3 and using online and electronic 
systems developed by various international organizations 
to reassess estimates and improve the efficiency of import 
and export procedures.4 To improve the accessibility and 
availability of controlled medicines in national health sys-
tems, measures such as electronic prescribing and insti-
tuting national health insurance and price-setting systems 
for essential medicines could be introduced.
2 UNODC, “An expanding synthetic drugs market – Implications for 
precursor control”, Global SMART Update, vol. 23 (March 2020).
3 International Narcotics Control Board and World Health Organization, 
Guide on Estimating Requirements for Substances under International 
Control (2012).
4 This includes the National Drug Control System (NDS) and the 
International Import and Export Authorization System (I2ES).
2 GLOBAL SYNTHETIC DRUGS ASSESSMENT 2020
Forensic capacities
The rapid evolution of the synthetic drug market, particu-
larly the large number of structurally diverse NPS, has 
marked a turning point in forensic science practice. As a 
result, the work of forensic scientists to analyse and identify 
a large number of unknown and sometimes structurally 
related substances without ambiguity has become much 
more complex. Moreover, potent synthetic opioids are 
often present only in trace amounts in drugs and prepara-
tions which makes their identification even more challeng-
ing. Enhancing national forensic capacities, including 
ensuring the availability of chemical reference materials, 
screening tools, and the use of validated forensic analytical 
technologies and methodologies are essential. 
Forensic intelligence
Samples of synthetic drugs often contain trace impurities 
of precursor chemicals essential to the drug manufactur-
ing process as well as by-products resulting from side reac-
tions.5 Through analysing the presence or absence of 
impurities in samples and the variations in impurity 
 profiles, forensic science can help identify the types of 
precursor chemicals and synthetic routes used in the 
manufacture of a sample.6 This supports not only the 
gathering of intelligence in the context of law enforce-
ment but also facilitates the monitoring of developments 
on the illicit drug market to inform drug and precursor 
control policies.7  
Law enforcement capacities and 
detection
The detection and identification of synthetic drugs are 
necessary first steps in any successful law enforcement 
intervention and key to the implementation of inter-
national drug control conventions at the national level. 
Synthetic opioids, for example, are easy to conceal and 
traffic, as only a few grams might be needed to produce 
thousands of doses. Very often, such substances are traf-
ficked through national or international mail or express 
consignment shipments, making interdiction challenging 
due to the large number of packages that cross borders 
5 UNODC, Drug Characterization/Impurity Profiling: Background and 
Concepts.
6 United Nations International Drug Control Programme, “Drug 
characterization/impurity profiling, with special focus on 
methamphetamine: recent work of the United Nations International 
Drug Control Programme.”, Bulletin on Narcotics, vol. LI, No. 1 and 2 
(1999), p. 103.
7 Pierre Esseiva and others, “Forensic Drug Intelligence: An Important 
Tool in Law Enforcement”, Forensic Science International, vol. 167, 
No. 2–3 (2007), pp. 247–254.
every day. Modern analytical technologies offer improved 
field identification capacity and limit the exposure of 
front-line officers to the potentially hazardous effects of 
handling some of these substances. Knowledge of modus 
operandi, synthesis methods, precursors and overall 
 trafficking patterns, as well as cross-border intelligence 
sharing in real time, allow for better analysis capacity and 
more complex investigations. With the Internet and 
 darknet being increasingly used as platforms for  supplying 
synthetic drugs, investments into strengthening the 
cybercrime capacities of law enforcement agencies are 
also an important consideration.
International and regional cooperation
Systematic international collaboration on a global level 
among all actors is crucial to addressing the challenges 
posed by an expanding synthetic drugs market. Such 
cooperation is fundamental to bridging information, 
capacity and resource gaps in order to address the syn-
thetic drug problem. Tools such as the UNODC Early 
Warning Advisory on NPS and the United Nations 
Toolkit on Synthetic Drugs8 also provide Member States 
and other stakeholders with a wide range of electronic 
resources to obtain information and address key chal-
lenges presented by synthetic drugs. 
Public-private partnerships
Strong public-private partnerships are essential to address 
the challenges posed by NPS and enable an effective pre-
cursor control regime. The continuing emergence of NPS 
creates the need for commercially available testing equip-
ment, toxicology screens and reference materials, as well 
as forensic and chemical expertise, to help forensic labora-
tories and law enforcement identify these new substances 
and verify their analysis.9 In addition, Governments might 
want to consider collaborating with academia and sup-
port the scientific research needed to generate evidence 
for potential national and international controls. In terms 
of the precursors used in illicit drug manufacture, private 
enterprises involved in the licit production, distribution, 
trade, financing and shipping of chemicals wield great 
influence and hold significant potential to be able to iden-
tify vulnerabilities in their supply chains and prevent the 
diversion of their products into illicit channels.10  
8 The United Nations Toolkit on Synthetic Drugs may be accessed at 
syntheticdrugs.unodc.org/
9 UNODC, “The growing complexity of the opioid crisis”, Global 
SMART Update, vol. 24 (September 2020).
10 UNODC, “An expanding synthetic drugs market – Implications for 
precursor control”, Global SMART Update, vol. 23 (March 2020).
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Health responses
A range of interventions and policies is needed to reduce 
risks to public health including, but not limited to, national 
drug prevention systems11 and the training and sensitiza-
tion of first responders. One important aspect is to scale up 
overdose prevention interventions and train first respond-
ers in overdose management, for example, the use of 
11 UNODC and WHO, International Standards on Drug Use Prevention, 
second updated edition (March 2018).
naloxone for the reversal of opioid overdose. Information 
sharing and promoting evidenced-based practices in terms 
of the spectrum of treatment and care interventions are 
essential to reduce the use of synthetic drugs including sub-
standard and falsified medicines. The removal of stigma 
through addressing stigmatizing attitudes to drug use and 
drug use disorders could also improve access to treatment, 
for example of opioid use disorders.12 
12 James D. Livingstone and others, “The effectiveness of interventions 
for reducing stigma related to substance use disorders: a systematic 
review”, Addiction, vol. 107, No. 1 (2012), pp. 39–50.
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IMPACT OF THE COVID-19 PANDEMIC ON THE SALE OF 
SYNTHETIC DRUGS 
The onset of the COVID-19 pandemic in late 2019 has 
brought about profound and wide-ranging effects on a 
global level. In an effort to contain the pandemic, govern-
ments around the world have closed non-essential parts 
of the economy and imposed border, travel and mobility 
restrictions which have had a detrimental effect on the 
global economy and many aspects of daily life. Although 
the synthetic drugs market is globally interconnected, the 
impact of the pandemic has proved to be less severe than 
initially expected. One major reason for this seems to be 
the high level of flexibility and adaptability shown by 
organized crime groups to change their business models 
and trafficking methods in response to market shortages 
and constraints. On the other hand, stringent social dis-
tancing policies and economic hardship may have had an 
adverse impact on localized (street level) supply and 
demand patterns. While it is likely that law enforcement 
operational capacities against illicit drug flows may be 
focused elsewhere or even lessened during the pandemic, 
the trafficking of drugs by container vessels or commer-
cial air freight seems to have continued without major dis-
ruption. Drug trafficking by post and parcel services also 
seems to have continued with some regions seeing 
increases in volumes. 13, 14
While it was expected that the lockdown in China would 
disrupt the supply of precursor chemicals for metham-
phetamine manufacture, vessels continued to ship large 
numbers of containers from East Asia to North America 
and Europe. As a result, smuggling opportunities within 
container traffic remained a viable and available transport 
option for illicit goods such as precursor chemicals.15 
Another mode of transport that increased significantly in 
East and South-East Asia was rail freight, as evidenced by 
greater volumes of Chinese rail freight across Central 
Asian and South-Eastern European rail networks in the 
first months of the pandemic.16 Similarly, media reports 
suggested potential disruptions to the supply of precursor 
chemicals for the illicit manufacture of fentanyl in Mexico, 
13 UNODC, Synthetic Drugs in East and South-East Asia: Latest 
Developments and Challenges (May 2020).
14 UNODC, “COVID-19 and the drug supply chain: from production 
and trafficking to use”, Research Brief (May 2020).
15 Global Initiative Against Translational Organized Crime, Jason Eligh, 
Crisis and opportunity, Impacts of the coronavirus pandemic on illicit drug 




but quantities seized at United States borders in early 
2020 did not change significantly compared to the previ-
ous year.17,18 A possible consequence of the  pandemic, 
however, is the risk that heroin shortages caused by 
 potential disruptions to trafficking routes from Latin 
America and South-West and South-East Asia may lead to 
the adulteration or substitution of heroin with cheaper 
and more harmful synthetic opioids with potentially seri-
ous adverse health consequences for users, especially if 
potent opioids such as fentanyl and its analogues are used 
for that purpose.19 With regard to methamphetamine, 
some reports indicate that initial disruptions in the supply 
of precursor chemicals to Mexico may have led to a rise in 
the price of methamphetamine sold in the United States. 
Nevertheless, total amounts of methamphetamine seized 
up to July 2020 remain higher compared to the same 
period in 2019, and disruptions, if any, appear to have 
been short-lived.20,21 
In Europe, no disruption in synthetic drug manufacture 
has been noted in Belgium or the Netherlands, as evi-
denced by the number of illicit laboratories dismantled 
and dump sites reported.22 However, the global demand 
for synthetic drugs used in recreational settings appears 
to have decreased due to the closure of bars and night-
clubs and the cancellation of music festivals, leading to a 
drop in wholesale prices of more than 20 per cent.23 
While the trafficking of “ecstasy” tablets from Western 
and Central Europe to the Caribbean and Central and 
South America has been disrupted due to a halt in air 
passenger transportation, possibly leading to higher 
retail prices in some countries, drug trafficking by com-
mercial air freight and shipping container vessels appears 
to be continuing, as evidenced by the comparatively 
17 UNODC, “COVID-19 and the drug supply chain: from production 
and trafficking to use”, Research Brief (May 2020).
18 Keegan Hamilton, “Sinaloa Cartel Drug Traffickers Explain Why 
Coronavirus Is Very Bad for Their Business”, Vice (23 March 2020). 
Available at www.vice.com/en_ca/article/bvgazz/sinaloa-cartel-drug- 
traffickers-explain-why-coronavirus-is-very-bad-for-their-business
19 UNODC, “The growing complexity of the opioid crisis”, Global 
SMART Update, vol. 24 (October 2020).
20 United States, Customs and Border Protection, CBP Enforcement 
Statistics Fiscal Year 2019, 2019. Available at www.cbp.gov/newsroom/
stats/cbp-enforcement-statistics-fy2019
21 United States, Customs and Border Protection, CBP Enforcement 
Statistics Fiscal Year 2020, 2020. Available at www.cbp.gov/newsroom/
stats/cbp-enforcement-statistics
22 European Monitoring Centre for Drugs and Drug Addiction, EU Drug 
Markets Impact of COVID-19 (May 2020).
23 Ibid. 
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large quantities of “ecstasy” seized recently on arrival in 
some South American countries. 
While governments are clearly attempting to address the 
economic, health and social problems caused by the 
pandemic with massive investment programmes, such 
reallocation of public resources may jeopardize recent 
efforts to strengthen drug prevention and treatment 
programmes. A reduction in resources to these pro-
grammes may render those at the margins of society 
even more vulnerable and undermine drug demand 
reduction efforts.24  
24 UNODC, Synthetic Drugs in East and South-East Asia: Latest 
Developments and Challenges (May 2020).
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TRENDS IN TRAFFICKING AND USE OF SYNTHETIC DRUGS
The synthetic drugs market is unique due to the simplic-
ity, flexibility and scalability of manufacture; the availabil-
ity of a wide variety of precursors and synthetic routes; 
the existence of a huge globalized, licit chemical and phar-
maceutical industry using similar substances and produc-
tion methods; and its independence from cultivation 
seasons and environmental conditions. Consequently, the 
affordability, availability and purity of synthetic drugs 
have increased, as have the health harms associated with 
their use. The synthetic nature of these substances also 
allows traffickers to market them in increasingly diverse 
forms of presentation: as powders, tablets, capsules, liq-
uids, impregnated blotter stamps, herbal material, sprays 
and in crystalline form. Synthetic drugs may therefore be 
ingested, smoked, inhaled, vaped, insufflated, injected, 
applied sublingually or used as patches, suppositories, eye 
drops or nasal sprays. 
The sheer number of more than 1,000 new psychoactive 
substances (NPS) which have emerged on illicit drug 
markets in recent years poses a serious challenge to 
users, health and emergency services and drug control. 
In addition, synthetic drugs are not always readily recog-
nizable as such as they may be presented as legitimate 
pharmaceuticals. Neither drug users nor traffickers have 
the means to differentiate between such a large number 
of substances, and drug control agencies and forensic 
laboratories need to invest continuously to keep up to 
date with new developments and trends. Patterns of use 
have also evolved with polydrug use on the increase. 
Furthermore, international criminal organizations are 
suspected of exchanging knowledge across continents 
on manufacturing and concealment methods as oppor-
tunities for trafficking offered by the darknet and the use 
of cryptocurrencies grow.
Methamphetamine:  
a dynamic and growing market
The methamphetamine market has expanded globally 
during the past few years with seizures more than doub-
ling from 100 tons in 2013 to 228 tons in 2018. 
The increase in quantities seized, together with falling 
retail prices and increased purity, point to a dynamic and 
growing market for the drug. North America and 
East and South-East Asia remain the two main hubs for 
methamphetamine trafficking. In 2018, the largest sei-
zures in North America were reported by the United 
States and Mexico, and in East and South-East Asia, 
by China and Thailand. In recent years methampheta-
mine trafficking has expanded to other regions with 
increasing quantities seized in countries in South-West 
Asia, South Asia, Central Asia and Transcaucasia, the 
Near and Middle East, Southern Africa, West Africa 
and Europe.
Methamphetamine is trafficked extensively within 
North America and East and South-East Asia, and to a 
lesser extent, Oceania. In addition, methamphetamine 
from North America is increasingly being trafficked to 
other parts of the world such as Europe, East and South-
East Asia, and Oceania. Moreover, significant quantities 
of precursors chemicals for methamphetamine manu-
facture are trafficked from East and South-East Asia to 
Oceania. 
While extensive methamphetamine manufacture has 
been reported in North America by Mexico and the 
United States as well as in East and South-East Asia, 
specifically the Golden Triangle, manufacture seems to 
have expanded in other regions including South-West 
Asia, Southern Africa, West Africa, and Western and 
Central Europe. In addition, organized criminal groups 
Figure 1 .  Global quantities of amphetamine- 
type stimulants seized, 2013–2018
Sources: UNODC, responses to the annual report question-
naire . Amphetamine data in 2018: Aggregate quantities 
seized; UNODC (2019), Subcommission on Illicit Drug Traffic 
and Related Matters in the Near and Middle East, Fifty-fourth 
session –Country Report: United Arab Emirates and Saudi 
Arabia. Individual seizures: Jordan Armed Forces – Arab Army 
























from Mexico seem to be involved in large-scale metham-
phetamine manufacture in Belgium and the Netherlands. 
Increases in quantities of crystalline methamphetamine 
seized and its higher purity, which is associated with 
higher health risks for users, has led to more severe nega-
tive health implications, growing demand for treatment 
and more methamphetamine-related deaths in some 
countries. 
Amphetamine: the growing impact of 
“captagon” 
Over the 2013–2018 period, global annual quantities of 
amphetamine seized fluctuated between 45 and 71 tons. 
However, fluctuations in quantities were mainly related to 
countries in the Near and Middle East, which have the 
largest amphetamine (“captagon”)25 market, whereas 
25  Tablets contain mostly amphetamine and caffeine.
Figure 2 .  Regional distribution of methamphetamine quantities seized, 2013–2015 and 2016–2018
Other regionsSouth-West AsiaNorth America East and South-East Asia, Oceania







Source: UNODC, responses to the annual report questionnaire .
Figure 3 . Regional distribution of amphetamine quantities seized, 2013–2015 and 2016–2018
Africa
Other regions
North AmericaNear and Middle East Europe
Central America, South America, Caribbean












Source: UNODC, responses to the annual report questionnaire .
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seizures in other regions have remained relatively stable. 
At the regional level, the largest annual quantities of 
amphetamine seized continue to be reported by countries 
in the Near and Middle East, particularly Jordan, Lebanon, 
Saudi Arabia and the United Arab Emirates. Most of the 
amphetamine seized in the region is reported to have 
originated in Lebanon and the Syrian Arab Republic. 
Instability and conflicts in the Near and Middle East seem 
to have nurtured the manufacture and trafficking of 
“ captagon” with both origin and destination typically 
being within the region, although “captagon” shipments 
sometimes transited other regions including Europe. 
An increase in amphetamine seizures was reported in 
Europe over the 2013–2018 period where in 2018, for the 
first time, more “captagon” tablets were seized than any 
other form of amphetamine. Europe has also seen an 
increase in amphetamine use in recent years. Most of the 
global supply of amphetamine is manufactured in the 
Near and Middle East and Europe, partly for domestic use 
and partly for trafficking to other countries. Similar to 
methamphetamine, retail prices for amphetamine 
decreased globally during this period, while its purity 
increased. 
An expanding market for “ecstasy” 
Sharp increases in the quantities of “ecstasy” seized have 
been reported in recent years, with global seizures more 
than doubling from 5 tons in 2013 to almost 12 tons in 
2018. Europe dominates global seizures in terms of 
quantities, followed by East and South-East Asia, 
Oceania and North America. The trafficking of “ecstasy” 
continues to expand with non-controlled precursor 
chemicals being used for its manufacture and increased 
quantities of seizures being reported by countries in 
Central Asia and Transcaucasia, North Africa, Southern 
Africa, Central America and the Caribbean. Large-scale 
manufacture of “ecstasy” has been reported in Europe, 
Figure 5 . Regional distribution of seized quantities of “ecstasy”, 2013–2015 and 2016–2018
Africa
Other regions
North AmericaEast and South-East Asia, OceaniaEurope
Central America, South America, Caribbean








Source: UNODC, responses to the annual report questionnaire .
Figure 4 .  Total amphetamine seizures  
reported worldwide, 2013–2018
Source: UNODC, responses to the annual report questionnaire .
*Aggregate quantities seized: UNODC (2019), Subcommission 
on Illicit Drug Traffic and Related Matters in the Near and Middle 
East, Fifty-fourth session – Country Report: United Arab 
Emirates and Saudi Arabia . Individual seizures: Jordan Armed 

























mainly in Belgium and the Netherlands, from where it is 
trafficked to consumer markets globally. In addition, 
first-time “ecstasy” manufacture has been reported in 
Southern Africa with clandestine laboratories disman-
tled in South Africa, and in South America manufacture 
of “ecstasy” was reported that also entailed the synthesis 
of MDMA and/or MDA. 
While “ecstasy” was previously a rather niche drug, it is 
now used by a broader range of people in mainstream 
 recreational nightlife settings. Products being sold as 
“ecstasy” have become increasingly diversified, with some 
tablets containing little or no 3,4-methylenedioxymeth-
amphetamine (MDMA) and others having extremely 
high MDMA content, as well as being sold in powder and 
crystalline form. As with other synthetic drugs, there is a 
global tendency towards purer and higher dose “ecstasy” 
products sold at the retail level. Whereas in the past a typ-
ical “ecstasy” pill often contained no more than 50-80 mg 
of MDMA,26 high dose “ecstasy” tablets nowadays can 
consist of more than 300 mg of MDMA and their use has 
been linked to severe adverse health consequences. As a 
result, the health risks associated with the use of “ecstasy” 
have risen significantly.
26 European Monitoring Centre for Drugs and Drug Addiction, Recent 
changes in Europe’s MDMA/ecstasy market – Results from an EMCDDA 
trendspotter study, Rapid Communication Luxembourg, Publications 
Office of the European Union, 2016.
Box 1. Environmental impact of illicit synthetic drugs manufacture 
Synthetic drug manufacture has a large negative environmental impact as a result of the waste created 
during the manufacturing process . Waste encountered at clandestine laboratories, as well as the safe han-
dling, storage and disposal of seized chemicals, presents unique problems to law enforcement and regula-
tory authorities .a Manufacturing 1 kg of amphetamine, for example, is estimated to generate between 20 
and 30 kg of waste .b Moreover, the illicit manufacture of alternative precursors also produces a significant 
amount of waste which is additional to the manufacture of the synthetic drug itself . Criminal organizations 
dispose of waste through burning, dumping it in the countryside or leaving it in abandoned residences . If 
this waste finds its way into the soil or water, it can have detrimental effects on the flora and fauna, as well 
as potentially on the quality of drinking water . Between 2015 and 2017, almost 660 illicit dump sites were 
notified to authorities in Belgium (68) and the Netherlands (591) .c
Clandestine laboratories are often found in locations where the immediate management of seized  chemicals 
is required in order to reduce risks to people and the environment . However, appropriate waste  management 
infrastructure and the necessary technical support may not always be available, particularly in remote 
 locations .d With the expansion of the synthetic drug market, the associated health and environmental risks, 
as well as the considerable costs associated with dismantling clandestine laboratories, are expected to 
grow .
Minimum estimated cost of dismantling/cleaning up synthetic drug production, 
storage and waste dump sites, in Belgium and the Netherlands, 2016




Source: Claessens, M ., Hardyns, W ., Vander Laenen, F . and Verhaeghe, N ., “An analysis of the costs of dismantling and  cleaning up 
synthetic drug production sites in Belgium and the Netherlands”, background paper for this report, European Monitoring Centre for 
Drugs and Drug Addiction, Lisbon, 2019 .
a UNODC, Guidelines for the Safe Disposal of Chemicals used in the Illicit Manufacture of Drugs (September 2011) .
b Europol, EU Manual on Illicit Synthetic Drugs/NPS Production, Europol, The Hague, 2019 .
c European Monitoring Centre for Drugs and Drug Addiction and Europol, EU Drug Markets Report 2019 .
d UNODC, Illustrated Guide for the Disposal of Chemicals used in the Illicit Manufacture of Drugs (October 2017) . 
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New psychoactive substances: 
expansion of synthetic opioids 
and benzodiazepine-type new 
psychoactive substances 
New psychoactive substances (NPS) are substances of 
abuse that have similar effects to drugs under inter national 
control. Up to August 2020, 125 countries and territories 
reported the emergence of more than 1,000 individual 
NPS. The NPS situation globally is characterized by a 
marked heterogeneity as 87 countries and territories have 
reported the emergence of fewer than 100 NPS while 10 
countries have reported more than 300 substances. Up to 
August 2020 and considering all NPS reported since 
monitoring began in 2008, stimulants constitute the 
 largest group of NPS at 35 per cent, followed by synthetic 
cannabinoid receptor agonists at 29 per cent. However, 
while the market share of stimulants reported increased 
slightly between 2018 and 2019, the market share and 
number of synthetic cannabinoid receptor agonists 
reported decreased at the same time, indicating a decrease 
in the diversity of substances within this effect group. 
Manufacture of NPS has been reported from countries in 
Europe, East and South-East Asia, Oceania, South Asia, 
South America, Southern Africa and most recently from 
Central Asia and Transcaucasia.
While the prevalence of use of NPS is rather low among 
the general population, the use of stimulants, synthetic 
cannabinoid receptor agonists, synthetic opioids and 
seda tives/hypnotics (mostly benzodiazepine-type NPS) 
is more common in high-risk drug users and marginalized 
groups such as people who inject drugs, the homeless and 
prison populations. It is likely that the health harms asso-
ciated with the use of NPS have increased with the emer-
gence of very potent substances which have the potential 
to lead to unintentional overdose events including fatali-
ties. The purity and composition of products containing 
NPS are often unknown, which places users at high risk as 
evidenced by hospital emergency admissions and deaths 
associated with NPS.
Interactions between the NPS market and traditional 
drugs have intensified with NPS being sold alongside or 
in mixtures with other drugs. In Central and South 
America for example, NBOMe compounds continue to 
be sold as LSD, and samples seized as 2C-B often contain 
other substances, such as ketamine, amphetamine, 
MDMA or a range of NPS. 
The number of synthetic opioids and sedatives/hypnotics 
appears to be growing and is associated with an increasing 
number of emergency-room cases and deaths. Over 80 
different synthetic opioids have been reported to 
UNODC since 2009, with fentanyl analogues being the 
dominant and fastest growing subgroup among NPS with 
opioid effects. However, the number of non-fentanyl- 
related synthetic opioids reported annually has also 
increased steadily in recent years, and in 2019 NPS with 
opioid effects reported to UNODC belonged to eight dif-
ferent chemical classes, indicating a growing chemical 
diversity of NPS with opioid effects on the market.27 
27 UNODC, “The growing complexity of the opioid crisis”, Global 
SMART Update, vol. 24 (October 2020).
















Source: UNODC, Early Warning Advisory on New Psychoactive Substances .
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Synthetic opioids have been found in blotters and in 
herbal smoking mixtures which may pose an elevated risk 
of overdose as the form of presentation does not give any 
indication that they contain potent opioids.
The number of NPS with sedative/hypnotic effects 
has  also increased with over 30 substances, mostly 
 benzodiazepine-type NPS, reported up to August 2020. 
Benzodiazepine-type NPS are often sold at very low 
prices, sometimes mimicking medicines in shape, with 
variable dosages of active ingredients, possibly containing 
contaminants, as well as highly potent synthetic opioids. 
There have also been reports from Europe of such sub-
standard and falsified medicines being produced by the 
same organized crime groups that manufacture and/or 
traffic synthetic drugs, such as MDMA, LSD and keta-
mine. Given their sedative/hypnotic nature, their use 
alone or in combination with other drugs may impair 
driving capabilities.28 Etizolam,29 flualprazolam30 and flu-
bromazolam were the benzodiazepine-type NPS most 
frequently reported to UNODC in the context of driving 
under the influence of drugs. In most cases, other drugs 
such as cannabis, cocaine, MDMA, amphetamine, 
 methamphetamine and prescription benzodiazepines 
(e.g.,  alprazolam, clonazepam, diazepam or lorazepam) 
were also detected. 
28 UNODC, Current NPS Threats, vol. II ( January 2020).
29 Etizolam has been under international control as of November 2020.
30 Flualprazolam has been under international control as of November 
2020.
The non-medical use of opioids is 
expanding: fentanyl and tramadol
Over the past years there have also been significant increases 
in the non-medical use of opioids including fentanyl and 
tramadol. Over the period 2013 to 2018, global tramadol 
seizures ranged from 9 to 125 tons with the largest quanti-
ties being seized in West and Central Africa, North Africa, 
and the Near and Middle East. Increasing quantities have 
also been reported from Central Asia and Transcaucasia. 
Almost half of all countries in Africa have reported 
non-medical use, seizures or trafficking of tramadol. The 
non-medical use of tramadol has become a growing con-
cern in the region, particularly among men, young people 
and manual or construction workers. Tramadol seized in the 
Near and Middle East seems to be mostly trafficked from 
North Africa and South Asia to the region for domestic use. 
The trafficking and non-medical use of fentanyl and its ana-
logues continue to pose serious threats to drug control and 
public health, especially in North America, where deaths 
involving fentanyl and its analogues remain a significant 
concern. Global seizures of fentanyl grew from 25 kg in 
2014 to 3 tons in 2018. Most significantly, quantities of 
 fentanyl seized in North America have grown sixfold from 
about 0.4 tons in 2016 to 2.9 tons in 2018, mainly in the 
United States. Information from law enforcement suggests 
that fentanyl in the United States is primarily sourced from 
China or Mexico and is often trafficked into the country in 
the form of powders or falsified prescription tablets. 
Increasing quantities of fentanyl have also been reported by 
countries in Europe and East and South-East Asia. 























Source: UNODC, Early Warning Advisory on New Psychoactive Substances .
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TRENDS IN THE MANUFACTURE OF SYNTHETIC DRUGS
The manufacture of synthetic drugs requires the conver-
sion of precursor chemicals into the finished drug. 
This conversion can be effected in one or more steps and 
can be mediated by a variety of chemicals and reagents. 
As a result, the illicit manufacture of amphetamine- 
type stimulants (ATS) such as 3,4-methylenedioxy-
methamphetamine (MDMA), amphetamine or 
 methamphetamine is highly flexible. This is illustrated 
by the fact that 14 of the 22 precursor chemicals listed in 
Table I of the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 (“1988 convention”) are precursors 
for amphetamine-type stimulants (ATS) and that the 
total number of precursor chemicals in Table I of the 
1988 convention has increased by eight (57 per cent) 
since 2014, including the 2020 decision to place methyl 
alpha-phenylacetoacetate (MAPA) under international 
control.
A decade ago, the primary precursors used for the manu-
facture of methamphetamine were pseudoephedrine 
and ephedrine. These substances are widely used in 
pharmaceuticals and thus their diversion from licit manu-
facture, either in bulk form or as pharmaceutical prepa-
rations, was the main source of precursors for illicit 
manufacture. The other main precursor chemicals used 
for the manufacture of amphetamine and methampheta-
mine are 1-phenyl-2-propanone (P-2-P) and its 
precursor phenylacetic acid. Since then, there have been 
two significant overlapping developments in precursor 
control: a switch from controlled to non-controlled 
 precursors and the use of “designer” precursors.
Apart from international scheduling decisions, these 
developments are influenced by a multitude of factors 
including different national precursor legislation and 
enforcement capabilities, discrepancies in precursor 
controls between neighbouring countries and the 
increasing versatility among illicit manufacturers to 
switch between alternative precursors and synthetic 
routes. These developments are not linear in nature 
however, and illicit manufacturers have switched back 
and forth between controlled, non-controlled and 
“designer” precursors. While the use of non-controlled 
precursors is not a recent development, the emergence 
of a large number of “designer” precursors in recent 
years is of major concern to the international 
community.31  
“Designer” precursors can be classified into two main 
groups: “masked” precursors and chemical intermediates. 
“Masked” precursors are chemical substances specifically 
designed to disguise controlled precursors from which 
31 UNODC, “An expanding synthetic drugs market – Implications for 
precursor control”, Global SMART Update, vol. 23 (March 2020).
Figure 8 .  Changes to tables of the United Nations Convention against Illicit Traffic in Narcotic 
















3,4 -MDP-2-P methyl glycidate (“PMK glycidate”), 
3,4-MDP-2-P methyl glycidic acid (“PMK glycidic acid”), 
alpha-phenylacetoacetamide (APAA) 
Source: United Nations, Tables of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 
of 1988, as at as at 4 March 2020, Commissions Resolutions and Decisions Database . Available at www .unodc .org/rddb/
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controlled precursors can easily be obtained. They may 
include derivatives of controlled precursors with varying 
degrees of complexity. Examples include derivatives of 
phenylacetic acid and P-2-P such as methyl phenylacetate, 
P-2-P bisulfite adduct and P-2-P methyl glycidate. Chemical 
intermediates on the other hand are chemical substances 
that are produced during the manufacture of drugs from 
precursors but are not typically isolated. When isolated, 
these chemical substances can themselves be considered 
precursors. Examples of these chemical intermediates 
include alpha-phenylacetoacetonitrile (APAAN), methyl 
alpha-phenylacetoacetate (MAPA) and chloroephedrine.
Figure 9 .  Evolution of the range of precursors and plants used in the illicit manufacture  
of amphetamine and methamphetamine 
1993 2017
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2009 2014 2015 2016
1,2-dimethyl-3-
phenylaziridine
Source: International Narcotics Control Board, various editions of the annual report on Precursors and chemicals frequently used 
in the illicit manufacture of narcotic drugs and psychotropic substances.
Note: The years indicate when a precursor was documented as a significant change or innovation, not necessarily when it was 
first used . 
*Common amphetamine/methamphetamine precursors including ephedrine, pseudoephedrine and 1-phenyl-2-propoanone (P-2-P) 
were already listed in Table I, and phenylacetic acid in Table II of the 1988 Convention when it came into force on 11 November 1990 .
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Regional diversity in amphetamine 
and methamphetamine precursor 
developments
Since the 1990s, illicit manufacturers in various parts of 
the world have complemented the use of traditional 
 precursors with the use of non-controlled precursors and 
“designer” precursor chemicals to circumvent national or 
international controls and the efforts of law enforcement 
and industry to prevent the diversion of chemicals.32 
Within this general trend, distinct national and regional 
variations can be observed due to factors such as differ-
ences in national precursor control regimes, illicit manu-
facturer capabilities and manufacturing costs. In East and 
South-East Asia, ephedrine and pseudoephedrine are the 
32 International Narcotics Control Board, various editions of the annual 
reports on Precursors and chemicals frequently used in the illicit manufacture 
of narcotic drugs and psychotropic substances. 
predominant precursors used in the manufacture of 
methamphetamine,33 however, recent seizures of 
2-bromopropiophenone34 (a non-controlled precursor 
for ephedrine),35 thionyl chloride36 (used for the manu-
facture of methamphetamine through the metal hydro-
genation process using ephedrine and 
pseudo ephedrine)37,38 and P-2-P39 indicate possible shifts 
in the types of precursor chemicals and synthetic routes 
33 UNODC, Synthetic Drugs in East and South-East Asia: Trends and Patterns 
of Amphetamine-type Stimulants and New Psychoactive Substances, 2019.
34 Ibid.
35 Ernest Fourneau, Process for the manufacture of phenyl-methyl-amino-
propanol (synthetic ephedrine), Patent GB 302,940 (December 1928).
36 UNODC, Transnational Organized Crime in Southeast Asia: Evolution, 
Growth and Impact, 2019.
37 Hilde Emde, “Diastereoisomerism, III, Chloro and bromo ephedrine”, 
Helvetica Chimica Acta, vol. 12, No. 1 (1929).
38 Hilde Emde, “Diastereoisomerism, I, Configuration of ephedrine”, 
Helvetica Chimica Acta, vol. 12, No. 1 (1929).
39 UNODC, Transnational Organized Crime in Southeast Asia: Evolution, 
Growth and Impact, 2019.























Not under international control
Placed in Table I  of 1988 Convention 2010-2020
Table I  of 1988 Convention prior to 2010
Schedule II, 1971 Convention
Source: UNODC elaboration . 
*Placed in Table I, 1988 Convention at the sixty-third Commission on Narcotic Drugs, March 2020 .
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used. The change in synthetic routes and additional levels 
of processing required for some of these new emerging 
 precursors also suggest increased sophistication among 
illicit manufacturing facilities in the region. In North 
America and Europe however, P-2-P synthetic routes 
dominate the illicit manufacture of amphetamine and 
methamphetamine.40 In North America, illicit manufac-
turers in Mexico have been observed in recent years to 
have switched back and forth between phenylacetic acid 
and its derivatives (“designer” precursors),41 benzalde-
hyde and nitroethane (general non-controlled precur-
sors)42,43 in the manufacture of P-2-P, possibly in response 
to national controls on these substances.44,45,46,47
In Europe, the use of chemical intermediates in the manu-
facture of P-2-P, such as alpha-phenylacetoacetonitrile 
(APAAN), alpha-phenylacetoacetamide (APAA) and 
methyl alpha-phenylacetoacetate (MAPA), all of which 
were recently placed under international control, has inten-
sified in recent years in order to circumvent controls on 
P-2-P, reduce manufacturing costs and ensure business 
continuity in illicit manufacturing.48,49 To a lesser extent, 
ephedrine and pseudoephedrine are the predominant pre-
cursors used in the domestic manufacture of 
40 International Narcotics Control Board, Precursors and chemicals 
frequently used in the illicit manufacture of narcotic drugs and psychotropic 
substances 2018 (United Nations publication, Sales No. E.19. XI.6).
41 UNODC, Clandestine Manufacture of Substances under International 
Control (United Nations publication, ST/NAR/10/REV.3).
42 Catherine B. Gairaud and Gerald R. Lappin, “The synthesis of 
ω-nitrostyrenes.”, Journal of Organic Chemistry, vol. 18, No. 1 (1953).
43 Joseph B. Tindall, Process for preparing 1-aryl-2-oxoalkanes, Patent US 
2,427,822 (September 1947).
44 International Narcotics Control Board, Precursors and chemicals 
frequently used in the illicit manufacture of narcotic drugs and psychotropic 
substances 2018 (United Nations publication, Sales No. E.19. XI.6).
45 International Narcotics Control Board, Precursors and chemicals 
frequently used in the illicit manufacture of narcotic drugs and psychotropic 
substances 2015 (United Nations publication, Sales No. E.16.XI.4).
46 International Narcotics Control Board, Precursors and chemicals 
frequently used in the illicit manufacture of narcotic drugs and psychotropic 
substances 2012 (United Nations publication, Sales No. E.13.XI.4).
47 United States, Department of Justice, Drug Enforcement 
Administration, 2018 National Drug Threat Assessment (Springfield, 
Strategic Intelligence Section, 2019).
48 European Monitoring Centre for Drugs and Drug Addiction and 
Europol, EU Drug Markets Report 2019 (Luxembourg, Publications 
Office of the European Union, 2019).
49 European Monitoring Centre for Drugs and Drug Addiction, Drug 
precursor developments in the European Union, EMCDDA Papers 
(Luxembourg, Publications Office of the European Union, 2019).
methamphetamine in Bulgaria, Czechia, Germany, Poland, 
Slovakia and the United States. 50,51,52,53
Precursor chemicals in the 
manufacture of “ecstasy”
Safrole, isosafrole, piperonal and 3,4-methylenedioxy-
phenyl-2-propanone (3,4-MDP-2-P, PMK), which are all 
controlled under the 1988 Convention, are the most used 
precursor chemicals for the manufacture of “ecstasy”. Of 
these, piperonal has the most widespread industrial use 
followed by safrole and isosafrole. Changes in the precur-
sor chemicals used for the manufacture of “ecstasy” in 
recent years parallel those in the manufacture of amphet-
amine and methamphetamine, in that a number of 
non-controlled chemicals have been primarily used in the 
illicit manufacture of 3,4-MDP-2-P. Principal among 
these “designer” precursors are 3,4-MDP-2-P methyl 
 glycidate and 3,4-MDP-2-P methyl glycidic acid, which 
have been increasingly found in seizures in Europe in 
recent years. Both precursors were placed in Table I of the 
1988 Convention in 2019. Given the similarity between 
P-2-P and 3,4-MDP-2-P, it is possible that many of the 
“designer” precursors produced for the manufacture of 
methamphetamine could also be produced for the manu-
facture of “ecstasy”. This is illustrated by the glycidate 
derivatives of 3,4-MDP-2-P mentioned above as well as a 
seizure of the “ecstasy” version of APAAN, namely 
3,4-methylenedioxyphenylacetonitrile, in France in 
2017.54 This is indicative of a crossover between the man-
ufacture of  different types of synthetic drugs and an 
example of the challenges faced by law enforcement and 
forensic personnel in investigating the clandestine manu-
facture of substances under international control.
50 European Monitoring Centre for Drugs and Drug Addiction and 
Europol, EU Drug Markets Report 2019 (Luxembourg, Publications 
Office of the European Union, 2019).
51 European Monitoring Centre for Drugs and Drug Addiction, Drug 
precursor developments in the European Union, EMCDDA Papers 
(Luxembourg, Publications Office of the European Union, 2019).
52 International Narcotics Control Board, Precursors and chemicals 
frequently used in the illicit manufacture of narcotic drugs and psychotropic 
substances 2018 (United Nations publication, Sales No. E.19. XI.6).
53 United States, Department of Justice, Drug Enforcement 
Administration, 2018 National Drug Threat Assessment (Springfield, 
Strategic Intelligence Section, 2019).
54 European Monitoring Centre for Drugs and Drug Addiction, Drug 
precursor developments in the European Union, EMCDDA Papers 
(Luxembourg, Publications Office of the European Union, 2019).
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Precursor trends in the illicit 
manufacture of fentanyl and its 
analogues 
In recent years there has been a significant increase in the 
number of fentanyl analogues appearing in synthetic drug 
markets. As a result, the primary precursor chemicals for 
the manufacture of fentanyl, N-phenethyl-4-piperidone 
(NPP) and 4-anilino-N-phenethylpiperidine (ANPP), 
were placed in Table I of the 1988 Convention in 2017. In 
the interim period, there are indications that illicit 
fentanyl manufacturers have begun switching to alterna-
tive synthetic routes involving the use of non- controlled 
and/or “designer” precursor chemicals.55,56 (For more 
information please see the section on North America.)
55 UNODC, Commission on Narcotic Drugs, “Decision 60/12 and 60/13: 
Inclusion of ANPP and NPP in Table I of the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 
1988.”, Report on the sixtieth session (2 December 2016 and 13–17 March 
2017), ECOSOC, Official Records, 2017, Supplement  No. 8, p. 39.
56 For further technical information on non-scheduled and “designer” 
precursors, please refer to UNODC, “An expanding synthetic drugs 
market – Implications for precursor control”, Global SMART Update, 
vol. 23 (March 2020).






Table I, 1988 Convention
Schedule I, 1961 Convention




Source: UNODC elaboration .













Placed in Table I of 1988 Convention 2010-2020
Table I of 1988 Convention prior to 2010
Schedule II, 1971 ConventionSource: UNODC elaboration .
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Key findings
Tramadol
• Almost half of all countries in Africa have reported non-medical use, seizures or trafficking of 
tramadol between 2015 to 2019 with most of them located in West, Central and North Africa .
• The non-medical use of tramadol has become a growing concern particularly among men, young 
people and manual or construction workers .
• Tramadol is trafficked mainly from Asia to countries in West, Central and North Africa .
• Large quantities of tramadol were seized in the period 2014–2019 with annual amounts fluctuat-
ing between 13 tons and 112 tons . The peaks in seizures, in several years, reflect huge individual 
shipments seized by some countries .
Methamphetamine
• The quantities of methamphetamine seized and the number of countries reporting seizures have 
increased over the past years mostly in West and Southern Africa .
• Methamphetamine manufacture in West and Southern Africa has expanded with 13 clandestine 
laboratories reported in 2018 . 
• Ephedrine and pseudoephedrine remain the primary precursors used in the illicit manufacture of 
methamphetamine .
• Methamphetamine from the region is mainly trafficked to East and South-East Asia, Oceania, 
and Western and Central Europe but some proportion remains in the region for domestic use .
• Use of methamphetamine is present among vulnerable populations and is associated with 
increased risk and harm .
“Ecstasy”
• For the first time in 2018, “ecstasy” manufacture has been reported from South Africa with two 
laboratories dismantled .
• There are indications of a growing “ecstasy” market in North and Southern Africa with annual 
increases in the quantities of “ecstasy” seized over the period 2014–2018 . 
• Increasing use of “ecstasy” has been reported among young people .
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• The quantities of “ecstasy” seized in the region remained stable with the highest seizures made 
in South America and small increases reported in Central America and some Caribbean 
countries .
• While “ecstasy” is mostly trafficked into the region from Western and Southern Europe, 
countries in the Caribbean and South America have reported “ecstasy” manufacture . 
• The “ecstasy” market has become more complex as tablets containing high doses of MDMA 
have emerged .
• MDMA is also available in powder and crystalline form, and “ecstasy” products may contain 
substances other than MDMA, including NPS with stimulant effects . 
New psychoactive substances
• In Central America, South America and the Caribbean, 210 NPS from 15 countries had been 
reported up to August 2020, mostly stimulants and classic hallucinogens . 
• In Central and South America, NBOMe compounds continue to be sold as LSD, reflected in 
forensic analysis of LSD samples .
• Samples sold as 2C-B or “cocaina rosada” in Central America and South America often contain 
other substances, for instance, ketamine, amphetamine, MDMA or a range of NPS .
Tranquilizers
• The non-medical use of tranquilizers such as benzodiazepines and barbiturates has been increas-
ing in Central and South American countries particularly among females, secondary school 
students and university students . 
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Key findings
Methamphetamine
• The quantities of methamphetamine seized in North America have continuously increased from 
about 58 tons in 2014 to almost 117 tons in 2018 .
• Extensive methamphetamine manufacture has been reported in Mexico and the United States . 
• Methamphetamine from Mexico is increasingly being trafficked to the United States and to other 
parts of the world such as Europe, East and South-East Asia and Oceania as indicated by 
seizures made in Mexico and destination countries . 
• Increasing availability of low-cost and high-purity methamphetamine is reported, as the number 
of drug poisoning deaths involving psychostimulants, mostly methamphetamine, has surged . 
• Methamphetamine use in the general population increased in the United States and Canada . 
• The risk of methamphetamine use is increasing due to the drug being sold as “ecstasy” and 
falsified Adderall® and Xanax® tablets .
Fentanyl and fentanyl analogues 
• Deaths involving synthetic opioids, especially fentanyl and its analogues, continue to remain a 
significant concern in North America .
• The quantities of fentanyl seized in North America have grown sixfold from about 0 .4 tons in 
2016 to 2 .9 tons in 2018 .
Precursors
• Alternate synthetic routes and non-scheduled precursor chemicals used in the illicit manufac-
ture of fentanyl have emerged in response to NPP and ANPP being placed under international 
control in 2017 .
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CENTRAL ASIA AND 
TRANSCAUCASIA
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Key findings
Methamphetamine
• The quantities of methamphetamine seized rapidly increased in the region during the past 
five years .
• Methamphetamine seized in the region reportedly originated from Iran (Islamic Republic of) and 
more recently from Afghanistan .
• Central Asia and Transcaucasia appears to be a transit point for methamphetamine trafficking to 
Africa, East Asia, North America and Oceania .
“Ecstasy”
• A geographic expansion of “ecstasy” was noted, with 7 out of 8 countries in the region reporting 
seizures in 2018 .
• A high number of reports indicate that “ecstasy” is trafficked from European countries including 
the Netherlands and Turkey to Central Asia and Transcaucasia .
New psychoactive substances 
• Several countries in Central Asia and Transcaucasia reported the emergence of NPS, with 119 
substances identified until August 2020 .
• After decreases in the number of NPS on the market in 2017 and 2018, the number of substances 
increased by 65 per cent in 2019 .
• The recent emergence of clandestine manufacturing of stimulants and synthetic cannabinoid 
receptor agonists might indicate an expanding NPS market in the region .
Synthetic opioids
• The appearance of synthetic opioids in Central Asia and Transcaucasia in recent years may 
suggest that the region is not immune to the opioid crisis, which mainly affects North America 
and parts of Africa .
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Key findings
Methamphetamine
• Synthetic drugs, in particular methamphetamine, dominate the illicit drug market in East and 
South-East Asia, the region with the fastest growing methamphetamine market in the world .
• Manufacture of methamphetamine around the Golden Triangle as well as in Cambodia and Viet 
Nam shows signs of expansion, while other countries in East and South-East Asia experience a 
corresponding decline in the number of clandestine laboratories seized . This phenomenon strongly 
indicates a consolidation of methamphetamine production in the Greater Mekong Subregion . 
• Despite record-setting seizures, the purity of methamphetamine is increasing while retail prices 
are decreasing in East and South-East Asia .
• Significant quantities of crystalline methamphetamine and precursor chemicals continue to be 
trafficked from East and South-East Asia to Oceania .
• Intensified effort in the trafficking of methamphetamine and associated precursor chemicals by 
transnational organized crime groups operating in East and South-East Asia region is a major 
driving force behind the increase in the region’s methamphetamine production and supply in 
recent years .
“Ecstasy”
• The use of “ecstasy” is not perceived as widespread . However, there is a growing availability of 
“ecstasy” in crystalline form as well as tablets containing high doses of MDMA trafficked from 
Europe .
• MDMA manufacture may be spreading from the maritime South-East Asian countries to some 
countries in the Greater Mekong Subregion .
• Tablet preparations sold as “ecstasy” but containing substances other than MDMA, including 
new psychoactive substances (NPS), continue to be found in the region .
New psychoactive substances 
• A total of 511 individual NPS were reported from countries in East and South-East Asia and 
Oceania to the UNODC Early Warning Advisory until August 2020 .
• Potent synthetic opioids including fentanyl and NPS with opioid effects are being identified and 
increasing annually in some countries in the East and South-East Asia and Oceania .
• Clandestine ketamine laboratories dismantled in a larger number of countries in South-East Asia, 
accompanied by substantial increases in seizures, point to a geographic shift of manufacture . 
GHB and GBL
• Seizures and increasing use of GHB and GBL are reported by some countries in East and South-
East Asia and Oceania . 
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• The largest quantities of amphetamine seized worldwide continue to be reported from Saudi 
Arabia, Jordan, United Arab Emirates and Lebanon (in order of aggregated amount seized) . 
• Most amphetamine seized in the region is reported to have originated in Lebanon and the Syrian 
Arab Republic, with manufacture reported from Jordan . 
• Europe plays an increasingly important role in “captagon” trafficking to and from countries in 
the Near and Middle East .
Methamphetamine
• Increases in quantities of crystalline methamphetamine seized in recent years suggest that the 
methamphetamine market in the region is expanding .
• Methamphetamine is trafficked from countries in East and South-East Asia, South Asia, and 
Western and Central Europe, to the Near and Middle East .
Tramadol 
• Non-medical use of tramadol continues to expand in countries in the Near and Middle East .
• Tramadol seems to be mostly trafficked to the region for domestic use from North Africa, West 
and Central Africa, and South Asia .
New psychoactive substances
• New psychoactive substances, mainly synthetic cannabinoid receptor agonists, continue to be 
reported from the region .  





• The ATS market in South Asia has expanded in recent years, with upward trends in the overall 
quantities of amphetamine, methamphetamine and ecstasy-type substances seized annually . 
• The supply-led expansion of ATS trafficking has seemingly led to growing ATS use in the region .
Methamphetamine
• The marked increase in methamphetamine seizures in the region is likely to be a result of grow-
ing transport connectivity within Asia, and intensification of methamphetamine manufacture 
and trafficking from neighbouring East, South-East and South-West Asia .
Precursors
• India’s booming pharmaceutical and precursor exports, combined with its scientific expertise 
and manufacturing capabilities, may present significant challenges for authorities in exercising 
controls over the diversion, clandestine manufacture and trafficking of precursor chemicals .
• Trafficking of ATS precursors from India remains significant, with key trafficking destinations 
including countries in Africa, East and South-East Asia, Oceania and the Near and Middle East . 
• Seizures of other synthetic drug precursors including N-acetylanthranilic acid, N-phenethyl-4-
piperidone (NPP) and 2-bromo-4-chloropropiophenone trafficked from or within India were also 
reported .





• The market for methamphetamine has seen a large increase across all countries in the region .
• Seizure quantities tripled from 1 .9 tons in 2016 to 6 .1 tons in 2018 and further increased in 2019 . 
• Key opiate trafficking routes in the region are being used to traffic methamphetamine towards 
other regions such as Asia, Europe, the Near and Middle East and Oceania .
• There appears to be a growing number of methamphetamine manufacturing facilities operating 
within Afghanistan, especially in the provinces bordering the Islamic Republic of Iran . 
• There are indications of increasing concomitant use of methamphetamine and opioids in the 
region while the perceived risks regarding the harm and dependence potential of methamphe-
tamine remain low among users .
Amphetamine
• Amphetamine remains a key fixture in Pakistan, with early indications of an expansion into 
Afghanistan .
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Key findings
Amphetamine
• Europe plays an increasingly important role in the global market for amphetamine with manufac-
ture remaining concentrated in the region, and subsequent trafficking to the Americas, Central Asia 
and Transcaucasia, East and South-East Asia, the Near and Middle East, North Africa and Oceania .
• Europe is possibly the origin of increasing amounts of “captagon” tablets destined for the Middle 
East and serves as a transit region for “captagon” trafficking from the Syrian Arab Republic to 
the Arabian Peninsula . 
• Amphetamine continues to be more commonly used than methamphetamine in most European 
countries .
Methamphetamine
• The availability of methamphetamine in Europe and its use has been slowly increasing and 
spreading geographically . 
• Methamphetamine manufacture has extended beyond Central Europe to Belgium and the 
Netherlands, with increasing evidence of the involvement of transnational organized crime 
groups . 
• The methamphetamine manufactured in Africa and Mexico transits through Europe, usually 
 destined for in East and South-East Asia and Oceania .
“Ecstasy”
• The quantities of “ecstasy” seized have almost doubled over the past five years, and the number 
of seizure cases is increasing .
• The MDMA content of “ecstasy” tablets has risen significantly increasing the risk associated with 
its use .
• “Ecstasy” tablets are manufactured in Europe and trafficked to consumer markets globally .
New psychoactive substances
• In Europe, 875 different NPS from 42 European countries had been reported by August 2020, 
mostly stimulants, synthetic cannabinoid receptor agonists and classic hallucinogens .
• Interactions between the NPS market and traditional drugs have become stronger, with NPS 
sold alongside or in a mixture with other drugs .
• Synthetic cannabinoids and synthetic cathinones continue to be used by high-risk and margin-
alized groups such as people who inject drugs, the homeless and prison populations .
• A larger number of synthetic opioids such as fentanyl analogues and benzodiazepine-type NPS 
have appeared on the NPS market and are associated with emergency-room and death cases . 
Precursors
• The continuous innovation of pre-precursor chemicals used in the manufacture of synthetic 
drugs prevails, as demonstrated by large shifts in the types and quantities of pre-precursors 
seized annually . 
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Glossary
Amphetamine-type stimulants: a group of sub-
stances composed of synthetic stimulants controlled 
under the Convention on Psychotropic Substances of 
1971 and from the group of substances called ampheta-
mines, which includes amphetamine, methamphetamine, 
methcathinone and the “ecstasy”-group substances 
(3,4-methylenedioxymethamphetamine (MDMA) and 
its analogues). 
Amphetamines: a group of amphetamine-type stimu-
lants that includes amphetamine and methamphetamine. 
Annual or past-year prevalence: the total number 
of people of a given age range who have used a given 
drug at least once in the past year, divided by the number 
of people of the given age range, and expressed as a 
percentage. 
Dependence: defined in the International Statistical 
Classification of Diseases and Related Health Problems 
(tenth revision) as a cluster of physiological, behavioural 
and cognitive phenomena that develop after repeated 
substance use and that typically include a strong desire 
to take the drug, difficulties in controlling its use, per-
sisting in its use despite harmful consequences, a higher 
priority given to drug use than to other activities and 
obligations, increased tolerance, and sometimes a physi-
cal withdrawal state. 
Drug use: use of controlled psychoactive substances for 
non-medical and non-scientific purposes, unless other-
wise specified. 
Harmful use of substances: defined in the 
International Statistical Classification of Diseases and 
Related Health Problems (tenth revision) as a pattern of 
use that causes damage to physical or mental health. 
New psychoactive substances: substances of abuse, 
either in a pure form or a preparation, that are not con-
trolled under the Single Convention on Narcotic Drugs of 
1961 or the 1971 Convention, but that may pose a public 
health threat. In this context, the term “new” does not 
necessarily refer to new inventions but to substances that 
have recently become available. For the purpose of the 
report, NPS that have been placed under international 
control since 2014 continue to be included under the 
term NPS to enable times series analysis.
Opiates: a subset of opioids comprising the various 
products derived from the opium poppy plant, including 
opium, morphine and heroin. 
Opioids: a generic term that refers both to opiates and 
their synthetic analogues (mainly prescription or pharma-
ceutical opioids) and compounds synthesized in the body.
People who suffer from drug use disorders/
people with drug use disorders: a subset of people 
who use drugs. Harmful use of substances and depend-
ence are features of drug use disorders. People with drug 
use disorders need treatment, health and social care, and 
rehabilitation. 
Prevention of drug use and treatment of drug 
use disorders: the aim of “prevention of drug use” is to 
prevent or delay the initiation of drug use, as well as the 
transition to drug use disorders. Once a person develops a 
drug use disorder, treatment, care and rehabilitation are 
needed.
Problem drug users: people who engage in the 
high-risk consumption of drugs . For example, 
people who inject drugs, people who use drugs on a daily 
basis and/or people diagnosed with drug use disorders 
(harmful use or drug dependence), based on clinical cri-
teria described in the Diagnostic and Statistical Manual of 
Mental Disorders (fifth edition) of the American 
Psychiatric Association, or the International Classification 
of Diseases and Related Health Problems (tenth revision) 
of WHO. 
Substance or drug use disorders: referred to in the 
Diagnostic and Statistical Manual of Mental Disorders 
(fifth edition) as patterns of symptoms resulting from the 
repeated use of a substance despite experiencing prob-
lems or impairment in daily life as a result of using sub-
stances. Depending on the number of symptoms 
identified, substance use disorder may be mild, moderate 
or severe. 
Synthetic drugs: includes any substance of synthetic 
origin with psychoactive effects available on the illicit 
drug market and/or used for non-medical purposes.
Synthetic opioids: fentanyl, fentanyl analogues and 
new synthetic opioids.
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* All references to Kosovo in this report should be understood to be in 
compliance with Security Council resolution 1244 (1999).
Regional groupings
The Global Synthetic Drugs Assessment 2020 uses a number 
of regional and subregional designations. These are not 
official designations, and are defined as follows: 
Africa
• East Africa: Burundi, Comoros, Djibouti, Eritrea, 
Ethiopia, Kenya, Madagascar, Mauritius, Rwanda, 
Seychelles, Somalia, South Sudan, Uganda, United 
Republic of Tanzania and Mayotte 
• North Africa: Algeria, Egypt, Libya, Morocco, Sudan 
and Tunisia 
• Southern Africa: Angola, Botswana, Eswatini, 
Lesotho, Malawi, Mozambique, Namibia, South 
Africa, Zambia, Zimbabwe and Reunion 
• West and Central Africa: Benin, Burkina Faso, Cabo 
Verde, Cameroon, Central African Republic, Chad, 
Congo, Côte d’Ivoire, Democratic Republic of the 
Congo, Equatorial Guinea, Gabon, Gambia, Ghana, 
Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, 
Niger, Nigeria, Sao Tome and Principe, Senegal, 
Sierra Leone, Togo and Saint Helena 
Americas
• Caribbean: Antigua and Barbuda, Bahamas, 
Barbados, Cuba, Dominica, Dominican Republic, 
Grenada, Haiti, Jamaica, Saint Kitts and Nevis, Saint 
Lucia, Saint Vincent and the Grenadines, Trinidad 
and Tobago, Anguilla, Aruba, Bonaire, Netherlands, 
British Virgin Islands, Cayman Islands, Curaçao, 
Guadeloupe, Martinique, Montserrat, Puerto Rico, 
Saba, Netherlands, Sint Eustatius, Netherlands, Sint 
Maarten, Turks and Caicos Islands and United States 
Virgin Islands 
• Central America: Belize, Costa Rica, El Salvador, 
Guatemala, Honduras, Nicaragua and Panama 
• North America: Canada, Mexico and United States of 
America, Bermuda, Greenland and Saint-Pierre and 
Miquelon 
• South America: Argentina, Bolivia (Plurinational 
State of), Brazil, Chile, Colombia, Ecuador, Guyana, 
Paraguay, Peru, Suriname, Uruguay, Venezuela 
(Bolivarian Republic of) and Falkland Islands 
(Malvinas) 
Asia
• Central Asia and Transcaucasia: Armenia, Azerbaijan, 
Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, 
Turkmenistan and Uzbekistan 
• East and South-East Asia: Brunei Darussalam, 
Cambodia, China, Democratic People’s Republic of 
Korea, Indonesia, Japan, Lao People’s Democratic 
Republic, Malaysia, Mongolia, Myanmar, 
Philippines, Republic of Korea, Singapore, Thailand, 
Timor-Leste, Viet Nam, Hong Kong, China, Macao, 
China, and Taiwan Province of China 
 – Greater Mekong Subregion: Cambodia, China, 
Lao People’s Democratic Republic, Myanmar, 
Thailand and Viet Nam
• South-West Asia: Afghanistan, Iran (Islamic Republic 
of) and Pakistan 
• Near and Middle East: Bahrain, Iraq, Israel, Jordan, 
Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, State 
of Palestine, Syrian Arab Republic, United Arab 
Emirates and Yemen 
• South Asia: Bangladesh, Bhutan, India, Maldives, 
Nepal and Sri Lanka 
Europe
• Eastern Europe: Belarus, Republic of Moldova, 
Russian Federation and Ukraine 
• South-Eastern Europe: Albania, Bosnia and 
Herzegovina, Bulgaria, Croatia, Montenegro, North 
Macedonia, Romania, Serbia, Turkey and Kosovo*  
• Western and Central Europe: Andorra, Austria, 
Belgium, Cyprus, Czechia, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, 
Ireland, Italy, Latvia, Liechtenstein, Lithuania, 
Luxembourg, Malta, Monaco, Netherlands, Norway, 
Poland, Portugal, San Marino, Slovakia, Slovenia, 
Spain, Sweden, Switzerland, United Kingdom of 
Great Britain and Northern Ireland, Faroe Islands, 
Gibraltar and Holy See 
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Oceania
• Australia and New Zealand: Australia and New 
Zealand
• Polynesia: Cook Islands, Niue, Samoa, Tonga, Tuvalu, 
French Polynesia, Tokelau and Wallis and Futuna 
Islands 
• Melanesia: Fiji, Papua New Guinea, Solomon Islands, 
Vanuatu and New Caledonia 
• Micronesia: Kiribati, Marshall Islands, Micronesia 
(Federated States of), Nauru, Palau, Guam and 
Northern Mariana Islands
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